Aflibercept (INN USAN) is a biopharmaceutical drug invented by Regeneron Pharmaceuticals approved in the United States and Europe for the treatment of wet macular degeneration under the trade name Eylea and for metastatic colorectal cancer as Zaltrap.
This page contains content from the copyrighted Wikipedia article "Aflibercept"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.